EHA 2024 | Results from 5 Studies Selected for Presentations

Ascentage Pharma (6855.HK) announced today that the latest results from five studies have been selected for Poster Presentations at the 2024 European Hematology Association Hybrid Congress (EHA 2024). These posters will feature olverembatinib (HQP1351), the first and only China-approved third-generation BCL-ABL1 inhibitor; investigational lisaftoclax (APG-2575), a Bcl-2 selective inhibitor; and investigational APG-5918, an EED selective inhibitor.The European Hematology Association (EHA) Hybrid Congress is the largest gathering of the hematology field in Europe. It showcases the most cutting-edge research and state-of-the-art innovative therapies, attracting over 10,000 clinical experts and researchers from more than 100 countries every year. This year, the EHA Hybrid Congress will take place on June 13 - 16, 2024, in Madrid, Spain.Dr. Yifan ZhaiChief Medical Officer of Ascentage PharmaI am delighted to showcase the strength and progress of Ascentage Pharma in hematology at this year ………………………………